Navigation Links
Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
Date:9/5/2007

Imaging Diagnostic Systems Installs CTLM(R) in Tianjin, China

FORT LAUDERDALE, Fla., Sept. 5 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer in laser optical breast cancer imaging systems, has installed a CT Laser Mammography (CTLM(R)) system at the Tianjin Medical University's Cancer Institute and Hospital, the largest breast disease center in China.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

Research at the Cancer Institute will be led by Professor Bao Runxian, Director of Radiology. Data will be collected under three research protocols designed to improve current methods of addressing breast cancer imaging and treatment follow-up. Professor E. Milne, MD, IMDS Director of Clinical Research will train the University doctors on CTLM adjunctive image interpretation and protocol methodologies.

The Tianjin system is the second research system installed in China. The first, at Beijing's Friendship Hospital, enabled CTLM clinical procedures to become listed on the Regional schedule for patient payments. IMDS plans to install several more research CTLM systems in China to accelerate market adoption of the new laser breast imaging technique.

Both the incidence and the number of deaths from breast cancer has tripled in Chinese women, making it the second most common cause of death from cancer for Chinese women. Early detection may provide women with better treatment options. Sources in China report that the incidence of breast cancer in has increased by at least 27% over the past decade and 40% of the Chinese women diagnosed with breast cancer die within five years because the cancer is already very advanced when it is diagnosed.

The Cancer Institute and Hospital is planning the 4th Congress of the World Society for Breast Health, in Tianjin, October 18th through October 21st. The Congress is sponsored by the World Society for Breast Health, the China Oncology Society and the Chinese Medical Association. IDSI Beijing will present CTLM clinical findings at the meeting.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our website: http://www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:

Rick Lutz

(404) 261-1196

lcgroup@mindspring.com

Media Contact:

Elizabeth Williams

(954) 581-9800

williams@imds.com


'/>"/>
SOURCE Imaging Diagnostic Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The worlds largest factory
2. Brady continues growth through Asian acquisition
3. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
4. Cancer siRNA Oligo Set Version 1.0
5. Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform
6. Detection of Mutant K-ras in a Kindred With Hereditary Pancreatic Cancer by DGGE
7. Detection of p53 Gene in Breast Cancer by Denaturing Gradient Gel Electrophoresis and the DCode System
8. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
9. Genome Wide Profiling of Paired Cancerous and Normal Breast Tissues and Rapid Interpretation of Gene Expression Data
10. NeoClone gets $750K for ovarian cancer detection
11. Quintessence Biosciences advances cancer drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... (PRWEB) , ... January 12, ... ... disposable devices with short response times capable of performing routine electrochemical biosensing ... disposable screen-printed electrodes provide fast, sensitive detection and quantification of various analytes ...
(Date:1/12/2017)... , January 12, 2017 A new report published by Allied ... - Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that the global in vitro ... growing at a CAGR of 15.07% during the forecast period. ... ... ...
(Date:1/11/2017)... Mass. (PRWEB) , ... January 11, 2017 , ... ... in rural and urban clinics in Peru studying the pathogens that cause malaria ... her on a career path of discovery. , Now, as an assistant professor ...
(Date:1/11/2017)... ... January 11, 2017 , ... Microbial genomics ... microbiome studies. Its most recent microbiome impact grant award has been made to ... effect of long-term use of oral antibiotics, prescribed for skin conditions, on the ...
Breaking Biology Technology:
(Date:12/15/2016)... Canada and BADEN-BADEN, Germany , ... a leading global financial services provider, today announced an agreement ... passive behavioural biometrics, to join forces. The partnership will enable ... mitigation strategies in compliance with local data protection regulation. ... In order ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , ... expansion of its patent portfolio, which grew to over 40 granted and ... , , ... recently filed patent entitled " System, Device, and Method Estimating ... that enables device makers to forego costly hardware components needed to estimate ...
Breaking Biology News(10 mins):